Dr Anthony Wierzbicki DM DPhil

Anthony Wierzbicki is Senior Lecturer in Chemical Pathology and Director of the Lipid Unit at Guys’ and St. Thomas’ NHS Foundation Trust, London UK. His research interests include the molecular genetics of hyperlipidaemia, molecular diagnostics, the relationship of lipids to atherosclerosis and the role of lipids in peroxisomal and neurological disease (Refsum’s disease).

Dr Wierzbicki has authored more than 200 publications in the field of atherosclerosis. He is a Fellow of the National Association of Clinical Biochemistry (USA) and the American Heart Association (atherosclerosis and blood pressure sections). He is currently a trustee of HEART-UK and chairman of this charity’s medical and scientific committee, as well as a member of many national and international societies. He has sat on many UK government panels in cardiovascular medicine including the National Institute of Clinical Excellence.

Dr Anthony Wierzbicki trained at the University of Cambridge and attended clinical school in Oxford. He subsequently specialised in chemical pathology with training posts at the National Hospital for Neurology (Queen Square) where he developed an interest in the neurochemistry of metabolic disease. He was awarded a MRC fellowship to study the molecular biology of calcium channels involved in Lambert-Eaton syndrome at the Institute of Molecular Medicine in Oxford under Professor John Newsom-Davis FRS. After completion of his D. Phil he completed his training in Cardiff and the Westminster Hospitals and turned his knowledge of metabolic syndromes to cardiology and lipids.


Most recent publications:

Wierzbicki AS, Nishtar S, Lumb PJ, Lambert-Hammill M, Crook MA, Marber MS, Gill J. Waist circumference, metabolic syndrome and coronary artery disease in a Pakistani cohort. Int J Cardiol 2007 Aug 7
www.ncbi.nlm.nih.gov/sites/entrez

Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res 2007;4:143-150.
www.ncbi.nlm.nih.gov/sites/entrez


Most cited publications:

Mikhailidis DP, Wierzbicki AS. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002 ;18 (4):215-9
www.ncbi.nlm.nih.gov/sites/entrez

ER Pearson, Pruhova S, Tack CJ, Johansen A, Castleden HAJ, Lumb PJ, Wierzbicki AS, Clark PM, Lebl J, Pedersen O, Ellard S, Hansen T, Hattersley AT. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia 2005;48:878-85.
www.ncbi.nlm.nih.gov/sites/entrez

Wierzbicki AS, Reynolds TM, Gill K, Alg S, Crook MA. A comparison of algorithms for initiation of lipid lowering therapy in primary prevention of coronary heart disease. J Cardiovasc Risk 2000;7:63-71.
www.ncbi.nlm.nih.gov/sites/entrez